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Abstract Multicellular layers (MCLs) have previously been used to determine the pharmacokinetics of a variety of
different cancer drugs including paclitaxel, doxorubicin, methotrexate, and 5-fluorouracil across a number of cell lines. It is
not known how nanoparticles (NPs) navigate through the tumor microenvironment once they leave the tumor blood vessel.
In this study, we used the MCL model to study the uptake and penetration dynamics of NPs. Gold nanoparticles (GNPs)
were used as a model system to map the NP distribution within tissue-like structures. Our results show that NP uptake and
transport are dependent on the tumor cell type. MDA-MB-231 tissue showed deeper penetration of GNPs as compared to
MCF-7 one. Intracellular and extracellular distributions of NPs were mapped using CytoViva imaging. The ability of
MCLs to mimic tumor tissue characteristics makes them a useful tool in assessing the efficacy of particle distribution in
solid tumors.
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1 Introduction
Biomedical research on the use of materials called
‘‘nanoparticles’’ (NPs) for improved cancer imaging and
therapy has come a long way [1–4]. Such nanotechnology
platforms allow the development of cancer diagnosis and
treatment that is more effective with reduced side effects
[2, 3, 5–7]. The targeted delivery of treatments is the goal
of NP systems so that safer methods are used [8–12].
Among NPs, research on gold nanoparticles (GNPs) plays a
major role in cancer treatment because they can increase
the damage inflicted by radiation and chemotherapeutic
drugs, generate heat upon ultraviolet (UV) and near
infrared refection (NIR) radiation exposure, and hence
allow the eradication of cancer cells via thermal ablation,
and therefore improve drug delivery for those that are
water insoluble or unstable in vivo, and prolong the life-
time of drugs or imaging agents through NP surface
modification, so that drug loss due to rapid clearance and
metabolism is avoided [13–15]. For these reasons, GNPs
are being studied as prospective therapeutic agents in
cancer treatment options that include chemotherapy, radi-
ation therapy (RT), photothermal therapy (PTT), and
photodynamic therapy (PDT). These new findings
encourage the development of effective combinational
therapy in the battle against cancer [3]. The success of such
innovations relies on GNP distribution and penetration
throughout the tumor. To reach cancer cells in optimal
quantities, therapeutic agents must be delivered to tumors
through an imperfect blood vascular system cross vessel
walls into the interstitium followed by penetrating multiple
layers of tissue (see Fig. 1a, b) [16]. In this study, we used
multicellular layers (MCLs) to simulate tumor tissue to
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study the penetration and uptake of GNPs in a tumor-like
microenvironment.
The MCLs developed by Wilson and his colleagues
provide a quantitative method that permits direct assess-
ment of drug penetration through solid tissue [17, 18].
MCLs share several properties with solid tumors derived
from the same cell type, including a similar but not iden-
tical extracellular matrix (ECM) and tight junctions
between epithelial cells [19]. In addition, MCLs have been
shown to exhibit areas of hypoxia, necrosis, as well as
nutrient and proliferation gradients, and ECM generation
[20–22]. The development of MCL models has facilitated
quantification of drug penetration through solid tissue.
Although the direct in vivo assessment, when feasible, has
the advantage of duplicating the clinical environment most
closely, in vitro techniques offer the advantage of being
able to examine the distribution of agents of interest in the
absence of complicating factors such as pharmacokinetics
and hepatic metabolism which often differ between mice
and humans [22].
In this study, we examine for the first time the ability of
NPs to penetrate and distribute through an MCL, which is
designed to mimic the environment of solid tumor tissue
(see Fig. 2). The MCL offers a model to study the transport
of NPs across the tumor tissue once it leaves the blood
vessel (Fig. 1c). The success of NP-based imaging and
therapy depends on their delivery to tumor tissue through
blood vessels as illustrated in Fig. 1a. It is known that NPs
can leak out of tumor blood vessels and enter tumor tissue
as illustrated in Fig. 1b. In this study, we grew tissue-like
MCLs of up to 130–150 lm to study the NP transport and
uptake in tumor tissue (Fig. 2b). Since the proliferation of
tumor cells can outpace the proliferation of cells that form
blood vessels, vascular density can be reduced, and the
















Fig. 1 Use of MCL cell model to understand the NP transport
through the tumor tissue. a Transport of GNPs through the blood
vessels and enters tumor vasculature. The interface between tumor
vasculature and tumor tissue is highlighted with a yellow box. b GNPs
escape the tumor vasculature through leaky endothelial cells (1) and
enter tumor cells through ECM. c Description shown in B is modeled
using proposed MCL cell model. MCL act as a tumor tissue being fed











































Fig. 2 Growth of MCLs. a Diagrammatic representation of the
apparatus used to culture MCLs. Tissue culture inserts are held
suspended in stirred media (top left). The set-up was placed in a
humidified incubator with 5 % O2, 5 % CO2, and 95 % N2. After the
growth, GNPs were introduced into the media to investigate the NP
transport through tissue (top right). b A cross-section of an unstained
MCF-7 tissue. c A cross-section of a MCF-7 tissue stained with eosin
to map the ECM. Areas marked in green belong to ECM, while the
unstained regions represent cells. (Color figure online)
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possible [23–25]. In addition, previous studies have shown
that the presence of ECM in solid tumor tissue can affect
the transport of molecules into tumor cells [26–28]. These
MCLs would also consist of ECM which is similar but not
identical to ones in solid tumors [19]. Hence, our MCL
model creates a reasonable tumor microenvironment to
study NP transport in tumor tissue. Elucidation of NP
uptake and transport in tissue-like structures will bridge the
gap between in vitro single-layer cell models and the
in vivo tumor models.
2 Materials and Methods
2.1 Synthesis of GNPs
The GNPs were synthesized via the reduction of HAuCl4 by
sodium citrate, which is more commonly referred to as the
Turkevitch method [29]. By varying the amount of sodium
citrate, the method can yield NPs of varying sizes. In this
study, 20-nm particles were chosen since our future goal is to
use these NPs for gene delivery. The GNPs were characterized
by transmission electron microscopy (H7000; Hitachi Corp.
Tokyo, Japan), UV-spectroscopy (Lambda 40; PerkinElmer,
Waltham, MA), and by dynamic light scattering using 90 Plus
Particle Sizer Analyzer (Brookhaven Instruments Corp. New
York, NY) to determine the size of the particles.
2.2 Growth of MCLs
The growth of the MCLs began with the growth of monolayer
cells in a 5 % CO2 environment at 37 C. After reaching con-
fluence, these cells were trypsinized, centrifuged, suspended in
media, and counted. Approximately, 150,000–200,000 cells
were seeded onto a microporous membrane insert (Millicell,
Bedford, MA). After allowing the cells to attach for 2–4 h, the
inserts were washed with phosphate buffered saline (PBS) and
then suspended in stirred media to grow. With pore sizes of
3 lm, the inserts allowed for the passage of stirred media
through the base of the insert as seen in Fig. 2a.
Two breast cancer cell lines were used in this study: MCF-








































Fig. 3 Visualization and mapping of GNPs in cells using CytoViva HSI optical microscopy. a The unmapped dark-field HSI image with GNPs
visible as bright spots. b The result of a spectral angle mapping on the HSI image. GNPs have been labeled red as a result of matching spectra
from individual pixels. c GNP spectra from few NP clusters localized within cells and the reference spectra (inset) used to create the spectral
angle map in b. (Color figure online)
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Dulbecco0s Modified Eagle0s Medium (LifeTechnologies
Inc. Burlington, ON) with 10 % Fetal Bovine Serum (Sigma-
Aldrich, Oakville, ON). Figure 2b is an image of an
unstained tissue cross-section of MCF-7 cells. The ECM
within the tissue was stained with eosin for visualization
(Fig. 2c). The thickness of the tissue was controlled by the
growth period. MCL incubation with NPs was done by
hanging the MCLs in multiwall plates followed by filling the
top of the inserts with the GNP and media mixture. A supply
of fresh media was placed below the MCL to allow for GNPs
that had penetrated the entire MCL structure to diffuse.
2.3 Quantification of GNP Uptake
During incubation, the MCL structures were hung in
multi-well plates with a 15 nM GNP/media mixture on
the top and a supply of fresh media on the bottom. Both
the ‘top’ and ‘bottom’ volumes were collected and
measured for gold content via inductively coupled
plasma-atomic emission spectroscopy (ICP-AES) (Optima
7300 DV; PerkinElmer, Waltham, MA). By using the
known total concentration of GNPs, uptake and pene-
tration through tissue may be measured, which results
from taking the difference between the ‘top’ and ‘bot-
tom’ samples. Monolayer cultures were also grown and
harvested at three different time points or cell densities.
These cultures were incubated with GNPs for 24 h and
were used for cell counting and monolayer gold uptake
measurement via ICP-AES. To determine the uptake as a
function of layers, the difference in uptake between
consecutive days of growth was observed (Fig. 8b).
Because each new day of growth introduced new layers,
the difference in uptake between consecutive days
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Fig. 4 Characterization of monolayer and multilayer cell structures. a–b Comparison of growth curves for the MDA-MB-231 and MCF-7 cell
lines at monolayer and multilayer level, respectively. c–d A monolayer and multilayer cross-section of MDA-MB-231 cells stained with eosin to
highlight the ECM, respectively. Cell population doubling times for MCF-7 and MDA-MB-231 monolayer cell cultures were 38.83 and 37.10 h,
respectively. Cell population doubling times for MCF-7 and MDA-MB-231 multilayer cell cultures were 48.36 and 51.07 h, respectively. Error
bars represent the standard deviation and n = 3. There was no statistically significant difference via one-way ANOVA test between the
monolayer and multilayer groups (p = 0.6907 for MCF-7 and p = 0.3751 for MDA-MB-231)
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2.4 Qualitative Analysis
To qualitatively measure the distribution of the GNPs as
well as to provide a measure of MCL growth characteris-
tics, MCL inserts were frozen in OCT compound for sec-
tioning. The frozen MCLs were then sectioned (Cryostat
CM1900; Leica, Wetzlar, Germany) into 15–20-lm-thick
sections and placed onto slides for imaging. Tissue sections
were stained with eosin to show the presence of ECM
(Autostainer XL; Leica, Wetzlar, Germany). Stained tissue
sections were imaged using the CytoViva Hyperspectral
Imaging (HSI) dark-field microscope. By examining the
images acquired by HSI (Fig. 8c, d), a qualitative exami-
nation of the layer-by-layer penetration was deduced.
2.5 CytoViva Imaging of NP Distribution in MCLs
The CytoViva technology used in this study was specifically
designed for optical observation and spectral confirmation of
NPs as they interact with cells and tissues. The illumination
of the microscope system utilizes oblique angle illumination
to create high SNR dark-field images. Figure 3a is a dark-
field image of a group of cells with internalized GNPs. The
GNPs appear bright owing to their high scattering cross-
section. HSI was used in conjunction with the dark-field
microscope to obtain reflectance spectra from each pixel in
the dark-field image. Spectral Angle Mapping can be per-
formed to conduct a pixel-by-pixel matching of any spectra
obtained by the system. This procedure was used to create a
map of GNPs based on their reflectance spectra within the
sample. The hyperspectral image shows which HSI pixels
matched the known GNP spectrum within a given spectral
angle threshold set at 0.15 radians for this study. Figure 3b
shows the hyperspectral image with an overlaid spectral
angle map where the red dots represent matching GNP
spectra. Figure 3c shows reflectance spectra from one of the
red dots and the reference spectrum (white color) to which
pixels were matched. Reference spectrum was chosen from a
sample of GNP spectra collected via the HSI image. It is
representative of a typical GNP spectrum for the sample
studied. The background reflectance spectra from the cyto-
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Fig. 5 GNP uptake in monolayer cell models. a NP uptake per cell as a function of cell density. b Total uptake of NPs as a function of cell
density. c–d Samples of H&E stained monolayer MDA-MB-231 and MCF-7 cells with GNPs present mostly in the cells. Error bars represent the
standard deviation and n = 3. One-way ANOVA test over the cell densities for each cell line revealed that there was no significant difference in
NP uptake for the MDA cell line (p = 0.565) and for the MCF-7 cell line (p = 0.3541)
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the GNP clusters have a very distinct reflectance spectra
compared to the background.
3 Results and Discussion
In this study, we demonstrate for the first time the differ-
ences in GNP uptake between monolayer and tissue-like
MCL models. GNPs were used as a radiation dose
enhancer, anticancer drug carrier, and an imaging contrast
agent in cancer research as discussed in the introduction.
However, the success of NP-based imaging and therapy
depends on the efficiency of delivery of NPs tumor tissue
as illustrated in Fig. 1a. In this study, we investigated the
NP transport across tumor tissues by using MCL cell model
for the first time. It was successfully used to understand NP
diffusion in tissues. The results were consistent with drug
diffusion patterns observed in solid tumor in animal
models.
It is known that NPs can leak out through the disorga-
nized endothelial cells in tumor blood vessels and enter the
tumor tissue (Fig. 1b). In particular, this MCL model was
used to study the transport of NPs across the tumor tissue
once they leave blood vessels (Fig. 1c). The device used
for growing MCLs is shown in Fig. 2a. A tissue cross-
section of an approximately 150-lm-thick MCF-7 cell is
shown in Fig. 2b and 2c. An unstained tissue cross-section
is shown in Fig. 2b, while a tissue cross-section stained
with eosin to highlight the ECM is shown in Fig. 2c. We
used the CytoViva HSI technique to image the tissue and
NPs. Unlike other optical imaging techniques, HSI allows
us to map the GNPs via reflectance spectroscopy. This
imaging technology does not require optically labeling NPs
for their visualization. This is the first time that such
imaging technology was used to visualize GNP distribution
in tissue-like structures. Figure 3a shows the unmapped
dark-field HSI image with GNPs visible as bright yellow








Fig. 6 Differences in extracellular matrix (ECM) in MDA-MB-231 and MCF-7 tissue structures. a–c, MCL tissue of MCF-7 cells at 910 and
960 magnification, respectively. b–d, MCL tissue of MDA-MB-231 cells at 910 and 960, respectively. Differences in the ECM structure can be
seen at both magnifications. MCF-7 tissue had a much more organized ECM structure, while MDA-MB-231 tissue has a disorganized ECM
structure which allowed easy penetration of molecules into deeper tissues
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mapping on the HSI image. GNPs have been labeled red as
a result of matching spectra (shown as an inset figure in
Fig. 3c) from individual pixels. Figure 3c shows a few
spectra from GNP clusters displayed in Fig. 3a. This
imaging technique was used to map NP distribution
through the tissue. Our first goal was to investigate the
difference between monolayer and MCL cell models in
terms of growth before investigating the NP uptake and
transport.
We monitored the growth of monolayer and multilayer
cell samples over a period of time to understand the
difference between these two cell models. As shown in
Fig. 4, MCLs differ from the monolayer cultures in terms of
growth and ECM generation. Both cell lines show an
increase in population doubling time in the MCLs (Fig. 4a,
b). For example, the population doubling time increased
from 37 (at monolayer level) to 51 h (at multilayer level) for
MDA-MB-231, while it increased from 39 (at monolayer
level) to 48 h (at multilayer level) for MCF-7. Increase in
population doubling time has previously been demonstrated
for cell lines growing as solid tumors in vivo [30–32].
Though calculated doubling times were higher for the mul-
tilayer sample, there was no statistically significant differ-
ence via one-way analysis of variance (ANOVA) test
between the monolayer and multilayer groups (p = 0.6907
for MCF-7 and p = 0.3751 for MDA-MB-231). Earlier
work has shown that MCLs develop oxygen, proliferation,
and nutrient gradients that lead to deficiencies in their
availability across the MCL sample [20, 21, 33]. In the case
of monolayer cell cultures, the uniform availability of oxy-
gen and nutrients is likely a major contributor to the lower
doubling time [30, 34, 35]. Figure 4c, d shows that there is
significant increase in the presence of ECM (areas marked in
green) in MCLs in contrast to monolayer cell cultures. The
data are shown for the MDA-MB-231 cell line. Similar
results were obtained for the MCF-7 cell line as well. There
were major increases in the presence of ECM in the MCLs
for both cell lines. ECM in the MCLs also appears thicker and
more structured as compared to the monolayer ECM. In
addition, GNPs (yellowish brown small dot-like structures)
were mostly localized within cells in monolayer cell cultures
(Fig. 4c). However, GNPs were localized in both the ECM
and cells in the MCL cell cultures (Fig. 4d). Hence, one of
the goals of this study is to understand how ECM affects NP
transport at the tissue level.
We have also quantified NP uptake and transport in
monolayer and MCL models. At the monolayer level, NP
uptake per cell is mostly independent of cell density
(Fig. 5). We performed a one-way ANOVA over cell
densities for each cell line. This test revealed that there was
no significant difference in the means for the MDA-MB231
cell line (p = 0.565) and for the MCF-7 cell line
(p = 0.3541). A two-sample t test was also performed
between the two cell lines at each density. These tests
indicate that there is no significant difference in NP uptake
between cell densities over the 3 trials performed at a 5 %
significance level. This is likely due to the fact that GNPs
introduced into monolayer cultures have immediate access
to all cells thus enabling the efficient uptake of GNPs per
cell. For example, NPs did not need to be transported
through a dense ECM. Optical images showed that most of
the NPs were localized within the cells, and the presence of
ECM was minimal (Fig. 5b, c). In the next section, we will
discuss the differences in ECM generated for MCF-7 and
Fig. 7 GNP uptake in multilayer cell models. a Accumulation of
GNPs in tissue as a function of its thickness. NPs were able to
penetrate deep into tissue in MDA-MB-231 tissue due to the
breakdown in ECM matrix. In MCF-7 tissue, most NPs were
localized at the top layers and properly organized ECM acted as a
barrier for their transport deep into the tissue. b The normalized
percent increase in GNP uptake as a function of tissue thickness.
Error bars represent the standard deviation and n = 3
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MDA-MB-231 cell lines before discussing NP transport
through tissue structures.
The difference in ECM between the two MCL models
(MCF-7 and MDA-MB-231) was made apparent in Fig. 6
where both were stained with eosin and appear green when
viewed with a dark-field condenser. The ECM of MDA-MB-
231 appears far less organized than the ECM of MCF-7. The
ECM of MCF-7 presents ordered scaffolding with cells
separated in distinct layers throughout the structure (Fig. 6a,
c), whereas the cell layers are much less compartmentalized
in the MDA-MB-231 ECM (Fig. 6b, d). It has been sug-
gested that aggressively invasive tumor cells like MDA-MB-
231 secrete matrix-degrading proteinases that serve to break
down collagen [36–38]. The degradation of the collagen
network in the ECM has been shown to significantly
diminish the ability of the ECM to control the flow of
interstitial traffic [26, 39–41]. This breakdown of ECM is not
as apparent in the non-invasive MCF-7 cell line, and ECM
will act as a barrier for NP transport. It is clear that ECM of
different tumor cell lines can vary and these models will play
a bigger role in optimizing NP-based therapeutic and imag-
ing systems before moving into in vivo studies. In the next
section, we discuss how the differences in ECM can affect
NP transport through these tissue-like MCL models.
Our investigation of NP transport in tissue-like MCL
models shows that NP penetration in tissue is dependent on
Fig. 8 Mapping of NP transport through different layers of a thicker tissue. a A schematic depicting the multiple layers of a tissue cross-section.
b Accumulation of NPs in different layers of tissue. c–d Mapping of the NP distribution in MDA-MB-231 and MCF-7 tissue (with GNPs labeled
in red), respectively. e–f A sample of reflectance spectra of GNPs localized in ECM and cells, respectively. Error bars represent the standard
deviation and n = 3. (Color figure online)
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the tumor cell line, possibly due to the differences in their
ECM structure as discussed in the previous section (Fig. 7).
At monolayer cell cultures, there was a linear increase in
NP uptake as a function of cell density (Fig. 5). However,
we noticed a deviation from this linear increase in NP
uptake especially in MCF-7 multilayer structures (Fig. 7).
Two-sample t test was used to compare the GNP uptake for
each cell line at each thickness. The GNP uptake was found
to be significantly different only for the smallest thickness
(50–60 lm) with a p value of 0.047. For the other three
thicknesses, the difference between the total NP uptake was
not significant with p = 0.052 for 75–85 lm thickness,
0.063 for 90–110 lm thickness, and p = 0.091 for thick-
ness greater than 130 lm. We attribute such difference to
the fact that the lower thickness still allows for the clear-
ance of GNPs in both models. Only when tissue is thicker
does the effect become more pronounced due to its higher
resistance to penetration. This reduction in uptake as a
function of tissue depth is also apparent for a number of
anticancer drugs, and is likely a major contributor to
resistance to drugs in tumors [22, 42–44]. According to
Fig. 7, the MCF-7 multilayer structures had a much higher
resistance to GNP penetration as compared to the MDA-
MB-231 MCL structure. This variation in NP penetration
through MCLs generated from different cell lines could be
mainly due to the differences in their ECM as discussed
previously. In MDA-MB-231 tissue, NPs were able to
penetrate deeper due to breakdown in the ECM matrix.
However, MCF-7 tissue had a much more organized ECM,
and therefore, ECM acted as a barrier to NP penetration.
In the previous section, we discussed the accumulated
transport of NPs in tissues with different thicknesses
(Fig. 7). We were able to differentiate NP transport in
different layers of a thicker tissue quantitatively and
qualitatively (see Fig. 8). According to Fig. 8b, MDA-MB-
231 tissue allows higher NP penetration in contrast to
MCF-7. Figure 8c shows that MDA-MB-231 cells were
able to access NPs despite greater tissue depth. Transport
of NPs through MCF-7 tissue is illustrated in Fig. 8d and
fewer were found a depth of the tissue. This further
explains the outcome shown in Fig. 6. Using the CytoViva
microscope, we looked at the spectral differences between
NPs localized within the cell and in the ECM. The clus-
tering of NPs in the cells is expected as GNPs are known to
be grouped into endosomes upon entry into the cell via
receptor-mediated endocytosis [45, 46]. According to
Fig. 8e, f, NPs internalized by cells have an overall red
shift in the spectra as compared to NPs in the ECM. This
shows that most of the NPs in the ECM are still not
aggregated as compared to ones within cells. Hence, it is
important to optimize the transport of these NPs through
ECM in order for them to reach cells effectively. This is the
first time NP transport through tissue-like structures is
studied using MCL cell models.
There is a tremendous effort to incorporate NPs into
existing cancer therapeutic protocols. We have demon-
strated that MCL model can be used to study the transport
of novel NP-based systems to optimize their delivery to
tumor tissue. Our future goal is to study how the size and
shape of NPs affect their transport through the ECM using
this MCL model. Our preliminary studies showed that
smaller NPs display higher tissue penetration as compared
to larger NPs (supplementary section S2). This result is
consistent with previous in vivo data. For example, Pu-
vanakrishnan et al. investigated the in vivo tumor targeting
efficiency of pegylated gold nanoshells (GNSs) and gold
nanorods (GNRs) for single and multiple dosing [47]. The
results showed that the smaller GNRs accumulated in
higher concentrations in the tumor in comparison to larger
GNSs. Moreover, Zang et al. have shown that 20-nm GNPs
showed significantly higher tumor uptake than 40- and
80-nm GNPs [48]. These in vivo studies clearly show that
smaller NPs transport easily through the ECM in compar-
ison to larger NPs. The importance of this study is that we
showed that MCL model could be used to mimic NP
transport in tumor-like environments. Our results are con-
sistent with published in vivo data. This model can be used
to understand the transport and therapeutic response of NP
complexes prior to use in animal models. Our future goal is
to study how NP size and shape affect their transport
in vivo and correlate their transport within the tumor tissue
using our in vitro MCL model.
4 Conclusions
This work demonstrates the importance of understanding
the limitations of monolayer cultures in their ability to
predict the uptake and effectiveness of cancer treatments in
solid tumors. Furthermore, these results underscore the
importance of the ECM in terms of throughout tumor tis-
sue. By engaging these issues, GNP-based systems can be
designed for combined chemotherapy and radiation therapy
to better overcome the resistance to drugs and radiation
found in solid tumors [3]. This would accelerate such NP-
based innovations into clinics for the improved quality of
life of cancer patients.
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